All

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder
27 October 2021

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and diseases, today announced that the...

Read the press release
CattleEye Announce $2.5m Seed Investment
14 October 2021

CattleEye Announce $2.5m Seed Investment

Belfast-based livestock monitoring technology company CattleEye announced today that it has closed a $2.5m seed investment round from a syndicate led by Techstart Ventures and...

Read more
Digital Aquaculture Innovator Ecto Raises $7M in Series A Round from Rabobank and Aqua-Spark
14 October 2021

Digital Aquaculture Innovator Ecto Raises $7M in Series A Round from Rabobank and Aqua-Spark

Aquaculture data analytics disrupter Ecto has raised $7 million in financing led by the Rabo Food & Agri Innovation Fund and Aqua-Spark. New investor Seventure Partners also...

Read more
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
13 October 2021

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target...

Read the press release
CAPZA acquires a majority stake in Web Geo Services
30 June 2021

CAPZA acquires a majority stake in Web Geo Services

CAPZA Growth Tech invests in Web Geo Services to make it a leading international player in Geolocation Intelligence.

Read more
Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders
13 October 2021

Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25...

Read more
IDnow joins IDunion, the network initiative for digital identities funded by the Federal Ministry for Economic Affairs and Energy (BMWi)
8 July 2021

IDnow joins IDunion, the network initiative for digital identities funded by the Federal Ministry for Economic Affairs and Energy (BMWi)

IDnow, a leading European Platform-as-a-Service provider for identity verification, announces its participation in the IDunion network, which aims to build an open ecosystem...

Read more
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
5 October 2021

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase...

Read the press release
ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV – African Swine Fever Virus – infected pigs
9 September 2021

ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV – African Swine Fever Virus – infected pigs

Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine...

Read the press release